Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells
Molecular Therapy - Methods & Clinical Development · 2024-09 · 32 (3) · 101280
DOI: 10.1016/j.omtm.2024.101280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2024-09. Verfasst von Gina Blahetek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Adeno-associated virus (AAV) vectors have become the leading platform for gene delivery in both preclinical research and therapeutic applications, making the production of high-titer AAV preparations essential. To date, most AAV-based studies use constitutive promoters (e.g., CMV, CAG), which are also active in human embryonic kidney (HEK)-293 producer cells, thus leading to the expression of the transgene already during production. Depending on the transgene's function, this might negatively impact producer cell performance and result in decreased AAV vector yields. Here, we evaluated a panel of diverse microRNA (miRNA)-based shRNA designs to identify a highly potent artificial miRNA for the transient suppression of transgenes during AAV production. Our results demonstrate that insertion of miRNA target sites into the 3' UTR of the transgene and simultaneous expression of the corresponding miRNA from the 3' UTR of conventional AAV production plasmids (rep/cap, pHelper) enabled efficient silencing of toxic transgene expression, thereby increasing AAV vector yields up to 240-fold. This strategy not only allows to maintain the traditional triple-transfection protocol, but also represents a universally applicable approach to suppress toxic transgenes, thereby boosting vector yields with so far unprecedented efficiency.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), 1030 Vienna, Austria.
- Medical University of Vienna, Vienna BioCenter (VBC), 1030 Vienna, Austria.
Förderung
- Boehringer Ingelheim
Zitieren
APA
Blahetek, G., Mayer, C., Zuber, J., Lenter, M., & Strobel, B. (2024). Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells. Molecular Therapy - Methods & Clinical Development, 32(3), 101280. https://doi.org/10.1016/j.omtm.2024.101280
Vancouver
Blahetek G, Mayer C, Zuber J, Lenter M, Strobel B. Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells. Molecular Therapy - Methods & Clinical Development. 2024;32(3):101280. doi:10.1016/j.omtm.2024.101280
BibTeX
@article{Blahetek2024,
author = {Blahetek, Gina and Mayer, Christine and Zuber, Johannes and Lenter, Martin and Strobel, Benjamin},
title = {Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells},
journal = {Molecular Therapy - Methods & Clinical Development},
year = {2024},
volume = {32},
number = {3},
pages = {101280},
doi = {10.1016/j.omtm.2024.101280}
}
EUVIMED